We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

NMR-Based Index Helps Identify Normal-Weight Individuals at High Risk for Type 2 Diabetes

By LabMedica International staff writers
Posted on 23 Jun 2014
Print article
Data suggests that a new, nuclear magnetic resonance (NMR)-based diabetes risk index would improve risk assessment and intervention for at-risk patients, potentially preventing or slowing their progression to type 2 diabetes.

LipoScience, Inc. (Raleigh, NC, USA), a company pioneering a new field of personalized NMR diagnostics, has announced data demonstrating the utility of its NMR-based diabetes risk index (DRI) in identifying normal-weight individuals at high risk of progressing to type 2 diabetes (T2D). The data, presented in a poster session (1417-P) at the 74th Scientific Sessions of the American Diabetes Association (ADA) on June 13–17, 2014, in San Francisco (CA, USA), suggest that the DRI may enable more timely and focused risk assessment and intervention in at-risk individuals regardless of body weight.

"Many clinicians are challenged about how to effectively manage patients with 'intermediate' blood glucose levels ranging from 90–110 mg/dL, as within this range there is often ambiguity as to whether a patient will progress to type 2 diabetes," commented Margery Connelly, PhD, Vice President, Translational Research of LipoScience, "The ambiguity is particularly pronounced in normal-weight individuals, who do not typically present with overtly visible risk factors. With our simple-to-use diabetes risk index, clinicians now have a tool to help them identify high-risk patients."

The DRI test uses LipoScience's proprietary NMR-derived markers of insulin resistance, inflammation, and potentially impaired B-cell function to determine a patient's risk of progressing to T2D. The DRI provides a means to assess this risk at any given level of fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), or body mass index (BMI).

To develop the DRI assay, the investigators used NMR data collected at baseline from participants in the Multi-Ethnic Study of Atherosclerosis (MESA), then used data from the Insulin Resistance Atherosclerosis Study (IRAS) to verify its ability to stratify a patient's risk of progressing to T2D. To determine whether the DRI score was capable of identifying high-risk normal-weight individuals, they compared the percentage of patients progressing to T2D across quartiles of the DRI score in three BMI categories – normal weight (BMI <25), overweight (BMI 25–30), and obese (BMI ≥30). Regardless of the BMI category, as the DRI score increased there was an increased likelihood of becoming diabetic, even for subjects whose BMI was within the normal range. Furthermore, DRI added predictive value independently of BMI in both the MESA and IRAS populations.

"Even in the absence of being overweight, DRI can help healthcare providers make a more timely prediction of whether a patient is on the path toward developing diabetes, before blood glucose reaches so-called 'pre-diabetes' levels," noted William C. Cromwell, MD, Chief Medical Officer of LipoScience, "By providing more precise risk-assessment information, DRI can facilitate initiation of individualized patient management strategies, while motivating high-risk patients to take steps to lower their risk."

The 2014 ADA meeting also featured additional poster presentations (1196-P, 1345-P, 1415-P), in which LipoScience's NMR spectroscopy was used to develop inflammation and diabetes risk assessment tools.

Related Links:

LipoScience


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.